Fludase developer NexBio raided, documents seized

Armed and flak-jacketed federal agents descended on vaccine developer NexBio at 8 a.m. yesterday. They escorted employees to parking lots and allowed them to re-enter the building only briefly 40 minutes later. An FBI spokesman wouldn't reveal the type of crime being investigated, but some 20 cardboard boxes were apparently seized. The company is developing Fludase, a powdered inhaler flu treatment. NexBio has received tens of millions of dollars in NIH grants and contracts for the effort. After operating solely with government funding, the company has recently tried to raise money from investors. Story

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.